Product Description
ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. (Sourced from: https://clinicaltrials.gov/study/NCT06426680)
Mechanisms of Action: B7-H3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innolake Biopharm
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for ILB-3101](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Esophageal Cancer|Head and Neck Cancer|Ovarian Cancer|Prostate Cancer|Small Cell Lung Cancer|Small Cell Sarcoma|Soft Tissue Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Uterine Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CILB3101A101 | P1 |
Not yet recruiting |
Soft Tissue Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Small Cell Lung Cancer|Head and Neck Cancer|Prostate Cancer|Small Cell Sarcoma|Uterine Cancer|Esophageal Cancer|Ovarian Cancer |
2025-12-01 |
44% |